undamentalytics Newsletter
Sign in

Jaguar Health, Inc. (JAGX) stock

Add to watchlist

Add holding +

NASDAQ: JAGX Nasdaq Pharmaceuticals Next results ~November 12, 2026

C+ Fundamentals grade

Jaguar Health, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Jaguar Health, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Jaguar Health, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds7 adding, 0 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Jaguar Health files

Where Jaguar Health stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $28m, up 135.5% on a year earlier, slower than the 156.0% growth a quarter earlier. That growth ranks 2 of 47 among the pharmaceuticals companies we cover. Free-cash-flow margin rose to -24.0% from -234.3% a year earlier. Operating margin widened to -93.1% from -278.1%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 4 of our 7 financial-health checks.

Our model value for Jaguar Health is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 19, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Jaguar Health, Inc.'s trailing-twelve-month revenue grew 135.5% year on year, with a free-cash-flow margin of -24.0%. Where it stands out: revenue growth of 135.5% ranks 2 of 74 pharmaceuticals companies we cover. Where it lags: change in growth rate of -20.4pp ranks 65 of 74 pharmaceuticals companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 75.8% while net income fell 29.0%: a 105pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 135.5% over the last 12 months, against a median of 10.0% for pharmaceuticals companies we cover.
  • Margins widening. Operating margin is up 185.0 points on a year ago.

Things to watch

  • Growth slowing. The growth rate is 20.4 points lower than a quarter earlier.
  • Loss-making. Operating margin is -93.1%: costs exceed revenue.
  • Burning cash. Free cash flow was -24.0% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 1209% and a beta of 3.3 against the S&P 500.
  • Short interest rising. Shares sold short rose 546% in a month to 7.2% of tradable shares.

Latest results: FY2026 Q2

Filed August 19, 2026
Earnings per share
-$3297.00 against an average estimate of -$2667.00: missed by 23.6%
Revenue
$1m, down 58.9% on a year earlier
Share reaction
-10.5% in the first session after the results on August 19, 2026, against -0.6% for the S&P 500
Next report
November 12, 2026

Jaguar Health's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-38.6%
  • 1 week-75.8%
  • 1 month-85.2%
  • This year-99.8%
  • 1 year-99.9%
  • 5 years-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$27.8M
Operating margin
-93.1%
Net margin
-188.5%

Growth

Revenue growth
+135.5%
Change in growth rate
−20.4 pts

Cash

Free cash flow (TTM)
-$6.7M
FCF margin
-24.0%
Stock pay % of revenue
2.1%

Earnings

Last results
August 19, 2026
Next results (est.)
November 19, 2026

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Our research
  2. Announcement
  3. Agreement
  4. Agreement
  5. Agreement
  6. Agreement
  7. Announcement
  8. Agreement
  9. Announcement
  10. Announcement
  11. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Jaguar Health, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Jaguar Health, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.04 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.1 ~$36–$150 Left out: out of range vs price (0.12x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Jaguar Health, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025
Share price$418605465600.00$133209563136.00$26046562304.00$2840315648.00$141927184.00$144407808.00$61425000.00$5138437.50$118912.50$13256.25$488.77
Market value$5.83tn$3.30tn$682.4bn$75.5bn$89.3bn$235.6bn$347.9bn$64.0bn$26.1bn$31.2bn$1.1bn
+ Net debt (− = net cash)−$2m$3m$14m$24m$4m$8m$11m$28m$29m$28m$42m
Enterprise value$5.83tn$3.30tn$682.4bn$75.5bn$89.3bn$235.6bn$347.9bn$64.0bn$26.2bn$31.3bn$1.2bn
Multiples
Price / sales n/mn/mn/mn/mn/mn/mn/mn/mn/mn/m99.0x
Price / earnings ———————————
Price / free cash flow ———————————
EV / EBITDA ———————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

32 /100

Weak moat

How hard Jaguar Health's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -40.4% of total assets over 7 years.

  • Pricing power 12 / 20

    Gross margin has been a median 74.6%, moving by 21.9 percentage points (standard deviation) across 8 years.

  • Durability 10 / 20

    Operating margin has been a median -607.4%; its worst year was -5744.9%.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (37 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, after the close.

Analysts' consensus

No analyst estimates are published for Jaguar Health, Inc.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2025 −$2667.00 −$3297.00 −23.6%
Jun 2025 −$3743.25 −$3888.94 −3.9%
Mar 2025 −$5680.50 −$8767.50 −54.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 19, 2026

No numeric guidance in Jaguar Health, Inc.'s latest earnings release (filed August 19, 2026). Some companies give their outlook only on the earnings call.

Positioning

Short interest
7.2%
of tradable shares
Days to cover
0.02
at average volume
Short interest, 1 month
+546%
to October 15, 2026
Held by institutions
2%
of shares
Held by insiders
4.4%
of shares
Employees
47
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
JAGX−58%−92%−98%−89%−96%−100%
Industry peers (median)−18%−49%−13%−2%+9%−12%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
JAGX17%8%33%25%17%9%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
JAGX−91%−92%−98%−96%−97%−100%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from January 13, 2016 to November 2, 2026. Getting back needed a 90706941135257% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.88 – $971.25
From 52-week high
−99.9%
vs 50-day average
−85.8%
vs 200-day average
−99.3%
Volatility (1 year)
1209%
Beta vs S&P 500
3.31

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 11 down
typical move ±10.7%
After a week
0 up, 12 down
typical move ±13.9%
After a month
1 up, 11 down
typical move ±46.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 19, 2026 −10.5% −0.6% −5.9% −81.5%
May 20, 2026 +3.4% +1.2% −1.9% −22.2%
April 7, 2026 −2.7% +2.6% −1.0% −80.3%
May 15, 2025 −4.7% +1.1% −26.6% −44.1%
March 31, 2025 −4.8% +1.0% −4.2% +144.8%
November 13, 2024 −4.6% −0.6% −10.1% −11.1%
August 13, 2024 −10.8% +2.0% −1.7% −7.5%
August 14, 2023 −10.8% −0.6% −17.7% −44.9%
May 15, 2023 −31.6% −0.3% −28.8% −28.6%
March 27, 2023 −31.0% 0.0% −48.2% −51.3%
November 14, 2022 −6.7% 0.0% −18.7% −25.3%
May 10, 2022 −7.2% −1.4% −2.4% −15.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Jaguar Health, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Jaguar Health, Inc.
$0 $10M $20M $30M FY20 Q2 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY20 Q2: $6.5M Revenue (TTM), FY20 Q3: $8.3M Revenue (TTM), FY20 Q4: $9.4M Revenue (TTM), FY24 Q2: $10.2M Revenue (TTM), FY24 Q3: $10.5M Revenue (TTM), FY24 Q4: $11.7M Revenue (TTM), FY25 Q1: $11.6M Revenue (TTM), FY25 Q2: $11.8M Revenue (TTM), FY25 Q3: $11.8M Revenue (TTM), FY25 Q4: $11.5M Revenue (TTM), FY26 Q1: $29.6M Revenue (TTM), FY26 Q2: $27.8M $27.8M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY20 Q2 $6.5M
FY20 Q3 $8.3M
FY20 Q4 $9.4M
FY24 Q2 $10.2M
FY24 Q3 $10.5M
FY24 Q4 $11.7M
FY25 Q1 $11.6M
FY25 Q2 $11.8M
FY25 Q3 $11.8M
FY25 Q4 $11.5M
FY26 Q1 $29.6M
FY26 Q2 $27.8M
Revenue growth, TTM YoY Jaguar Health, Inc.
-50% 0% 50% 100% 150% 200% FY19 Q2 FY20 Q1 FY20 Q4 FY26 Q2 Revenue growth, TTM YoY, FY19 Q2: 39.1% Revenue growth, TTM YoY, FY19 Q3: 34.4% Revenue growth, TTM YoY, FY19 Q4: 30.8% Revenue growth, TTM YoY, FY20 Q1: -2.8% Revenue growth, TTM YoY, FY20 Q2: 8.2% Revenue growth, TTM YoY, FY20 Q3: 41.8% Revenue growth, TTM YoY, FY20 Q4: 62.5% Revenue growth, TTM YoY, FY25 Q2: 16.0% Revenue growth, TTM YoY, FY25 Q3: 12.5% Revenue growth, TTM YoY, FY25 Q4: -1.5% Revenue growth, TTM YoY, FY26 Q1: 156.0% Revenue growth, TTM YoY, FY26 Q2: 135.5% 135.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY19 Q2 39.1%
FY19 Q3 34.4%
FY19 Q4 30.8%
FY20 Q1 -2.8%
FY20 Q2 8.2%
FY20 Q3 41.8%
FY20 Q4 62.5%
FY25 Q2 16.0%
FY25 Q3 12.5%
FY25 Q4 -1.5%
FY26 Q1 156.0%
FY26 Q2 135.5%
Operating margin (TTM) Jaguar Health, Inc.
-600% -400% -200% 0% FY20 Q2 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY20 Q2: -439.8% Operating margin (TTM), FY20 Q3: -328.3% Operating margin (TTM), FY20 Q4: -283.9% Operating margin (TTM), FY24 Q2: -311.8% Operating margin (TTM), FY24 Q3: -288.5% Operating margin (TTM), FY24 Q4: -263.8% Operating margin (TTM), FY25 Q1: -277.3% Operating margin (TTM), FY25 Q2: -278.1% Operating margin (TTM), FY25 Q3: -278.5% Operating margin (TTM), FY25 Q4: -398.8% Operating margin (TTM), FY26 Q1: -89.0% Operating margin (TTM), FY26 Q2: -93.1% -93.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY20 Q2 -439.8%
FY20 Q3 -328.3%
FY20 Q4 -283.9%
FY24 Q2 -311.8%
FY24 Q3 -288.5%
FY24 Q4 -263.8%
FY25 Q1 -277.3%
FY25 Q2 -278.1%
FY25 Q3 -278.5%
FY25 Q4 -398.8%
FY26 Q1 -89.0%
FY26 Q2 -93.1%
FCF margin (TTM) Jaguar Health, Inc.
-15000% -10000% -5000% 0% FY16 Q4 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY16 Q4: -10258.4% FCF margin (TTM), FY18 Q4: -514.9% FCF margin (TTM), FY20 Q4: -162.9% FCF margin (TTM), FY24 Q2: -289.2% FCF margin (TTM), FY24 Q3: -276.8% FCF margin (TTM), FY24 Q4: -251.4% FCF margin (TTM), FY25 Q1: -256.7% FCF margin (TTM), FY25 Q2: -234.3% FCF margin (TTM), FY25 Q3: -220.8% FCF margin (TTM), FY25 Q4: -205.8% FCF margin (TTM), FY26 Q1: -25.5% FCF margin (TTM), FY26 Q2: -24.0% -24.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY16 Q4 -10258.4%
FY18 Q4 -514.9%
FY20 Q4 -162.9%
FY24 Q2 -289.2%
FY24 Q3 -276.8%
FY24 Q4 -251.4%
FY25 Q1 -256.7%
FY25 Q2 -234.3%
FY25 Q3 -220.8%
FY25 Q4 -205.8%
FY26 Q1 -25.5%
FY26 Q2 -24.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0 0 4 4 6 9 4 12 10 12 12 28
Gross profit — 0 0 3 2 2 6 2 10 8 10 8 23
EBITDA — −12 −14 −34 −30 −27 −25 −39 −32 −32 −29 −44 −24
Operating income −8 −12 −14 −34 −31 −29 −27 −41 −34 −34 −31 −46 −26
Net income −9 −16 −15 −22 −32 −39 −34 −0 −0 −0 −38 −54 −52
Diluted EPS −$0.18 −$1193730.99 −$0.08 −$838927.61 −$1210073.73 −$71134.37 −$23685.14 −$9286.68 −$3808.57 −$187.95 −$16.34 −$22.97 —
Growth (year on year)
Revenue — — −45.2% +>999% +1.3% +30.8% +62.5% −53.8% +175.8% −18.4% +19.8% −1.5% +135.5%
Margins
Gross margin — 52.2% 63.3% 79.8% 37.4% 33.9% 65.1% 46.2% 83.1% 79.1% 83.3% 67.2% 82.3%
EBITDA margin — <−999% <−999% −771.9% −668.1% −471.2% −265.5% −899.4% −271.3% −330.7% −247.5% −382.2% −86.3%
Operating margin — <−999% <−999% −785.3% −698.0% −501.3% −283.9% −939.1% −287.8% −351.3% −263.8% −398.8% −93.1%
Net margin — <−999% <−999% −503.7% −727.9% −667.3% −360.2% −1.2% −0.4% −0.4% −329.3% −465.4% −188.5%
Free-cash-flow margin — <−999% <−999% — −514.9% — −162.9% −806.8% −277.5% — −251.5% −205.8% −24.0%
Cash flow
Cash from operations −5 −14 −14 −10 −23 −20 −15 −35 −33 −33 −29 −24 −7
Capital spending 0 0 0 — 0 — 0 0 0 — 0 0 0
Free cash flow −5 −14 −15 — −23 — −15 −35 −33 — −29 −24 −7
Stock-based pay 0 1 1 1 2 3 3 4 3 2 2 1 1
Free cash flow after stock pay −6 −15 −15 — −25 — −18 −39 −36 — −31 −25 −7
Balance sheet
Cash 1 8 1 1 3 3 8 17 5 6 8 1 4
Total debt 0 6 4 15 27 7 16 28 34 36 36 43 16
Net debt (negative = net cash) −0 −2 3 14 24 4 8 11 28 29 28 42 12
Diluted shares — — — — — — — — — — 2m 2m —
Returned to shareholders
Buybacks — — — — 0 — — — — — — — —
Total returned — — — — 0 — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 7 checks passed · June 30, 2026
What it owns · $34m
Short-term assets $18mLonger-term assets $17m
What it owes, and who funded it · $34m
Short-term liabilities $25mLonger-term liabilities $4mShareholders' equity $5m
  • Short-term assets cover short-term liabilities $18m of assets due within a year against $25m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $18m short-term assets against $4m of longer-dated liabilities.
  • More cash than debt $4m of cash against $2m of debt.
  • Debt below 40% of shareholders' equity Debt is 35% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 211% to 35% over five years.
  • A year's operating cash flow covers at least 20% of debt −$7m of operating cash flow against $2m of debt.
  • Operating profit covers interest at least five times over Operating income of −$26m against $998,000 of interest.

From Jaguar Health, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
90.7%
of revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated JAGX VRCA SCLX SBFM BGM IMCC Median
Revenue, last 12 months $28m $30m $32m $35m $38m $39m $276m
Revenue growth, last 12 months 135.5% 106.2% −28.5% −2.7% 51.1% −0.7% 9.9%
Revenue growth, 3-year average 76.5% 52.2% −12.0% 34.5% — — 5.5%
Revenue growth, latest quarter −58.9% −53.8% −22.8% −1.6% — — 6.5%
Gross margin 82.3% 63.8% 55.5% 30.3% 16.6% 17.7% 62.0%
Operating margin −93.1% −93.6% <−999% −16.6% −33.2% −21.2% −5.9%
Operating margin, 3-year average −227.7% −312.8% −512.2% −16.5% — — −7.4%
Net margin −188.5% −102.8% <−999% −16.5% −52.6% −20.7% −7.3%
Cash from operations / revenue −24.0% −44.0% −54.1% −15.1% −6.3% 8.6% 10.2%
Free-cash-flow margin −24.0% −44.0% −70.7% −15.2% −10.4% 8.6% 8.6%
Free-cash-flow margin, 3-year average −182.5% −280.0% −2.8% −25.5% — — 7.4%
Stock pay / revenue 2.1% 11.6% 51.0% — 27.0% 0.0% 3.6%
Change in share count — 5.6% — 55.7% >999% 71.3% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth 135.5% 10.0% 2 of 74
Change in growth rate Growth -20.4pp -0.3pp 65 of 74
Gross margin Profitability 82.3% 59.8% 8 of 59
Operating margin Profitability -93.1% -5.9% 53 of 67
Net margin Profitability -188.5% -7.3% 65 of 75
Free-cash-flow margin Cash generation -24.0% 10.1% 59 of 74
Stock pay as % of revenue Cash generation 2.1% 3.6% 27 of 69
Long-term debt as % of assets Balance sheet 5.0% 23.8% 12 of 53

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Human Health $11.2M 96.9% ▼ 1.9%
Animal Health $353,000 3.1% ▲ 12.1%
Products and services
Line of business Revenue Share YoY
Products $11.3M 99.7% ▼ 1.9%
Mytesi $11M 97.0% ▼ 2.7%
Licenses $172,000 1.5% ▲ 33.3%
Canalevia $148,000 1.3% ▼ 7.5%
Neonorm $35,000 0.3% ▲ 25.0%

From Jaguar Health, Inc.'s 10-K filed April 7, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$15,933
Institutions reporting
7
Positions opened / closed
7 / 0

Top buyers and sellers, Q2 2026: 7 institutions bought and 0 sold ; the biggest buyer was UBS Group AG (+4,000 shares) . See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
UBS Group AG $12,000 4K 75.3% —
Tower Research Capital LLC (TRC) $3,480 1K 21.8% —
Sbi Securities Co., Ltd. $252 0K 1.6% —
Barclays PLC $168 0K 1.1% —
Wells Fargo & Company $15 0K 0.1% —
Leonteq Securities AG $15 0K 0.1% —
International Assets Investment Management, LLC $3 0K 0.0% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Jaguar Health, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 19, 2026 estimated from the company's past filing pattern, not announced

  • August 19, 2026
  • May 20, 2026
  • April 7, 2026
  • May 15, 2025
  • March 31, 2025
  • November 13, 2024

Recent SEC filings

Data status

When each part of this page on Jaguar Health, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Jaguar Health, Inc. in brief

What does Jaguar Health, Inc. do?
Jaguar Health, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Jaguar Health, Inc.'s stock ticker?
Jaguar Health, Inc. trades under the ticker JAGX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Jaguar Health, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Jaguar Health, Inc. reported revenue of $27.8M, 135.5% higher than a year earlier, according to its SEC filings.
What is Jaguar Health, Inc.'s free cash flow?
Jaguar Health, Inc.'s free-cash-flow margin is -24.0% of revenue over the trailing twelve months, ranking 59 of the 74 pharmaceuticals companies we cover.
Who are Jaguar Health, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are UBS Group AG, Tower Research Capital LLC (TRC) and Sbi Securities Co., Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Jaguar Health, Inc.'s market cap?
On December 31, 2025, Jaguar Health, Inc.'s market capitalisation was about $1.1B and net debt of $41.6M. Market figures come from third-party market data and may be delayed.
How much debt does Jaguar Health, Inc. have?
Jaguar Health, Inc.'s debt-to-equity ratio is 35.1%, from its latest balance sheet (211.1% five years earlier). The financial health section below sets out its other solvency checks.
Who are Jaguar Health, Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Jaguar Health, Inc. are Verrica Pharmaceuticals Inc., Scilex Holding Co, Sunshine Biopharma Inc., BGM Group Ltd. and IM Cannabis Corp. The side-by-side comparison below sets their revenue, margins and growth against Jaguar Health, Inc.'s.
When is Jaguar Health, Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Jaguar Health, Inc. announces its own schedule.